{"filing":{"accession_number":"0001214659-26-009162","cik":"0001643918","ticker":"BDRX","company_name":"Biodexa Pharmaceuticals Plc","form":"6-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"z7272616k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1643918/000121465926009162/z7272616k.htm"},"events":[{"id":21739,"run_id":19610,"accession_number":"0001214659-26-009162","anchor_item_number":"EX-99.1","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The exhibit announces the results of a General Meeting held on July 29, 2026, where all four shareholder resolutions were passed. Resolutions 1 and 4 authorize a share reorganization reducing outstanding shares by a factor of 10,000 and changing the ADS ratio from 500,000:1 to 50:1, effective July 30, 2026. Resolutions 2 and 3 grant directors authority to allot shares on a non-pre-emptive basis. This is a classic shareholder vote result disclosure under Item 5.07 equivalent, and the share reorganization is material to investors' understanding of capitalization and ownership structure.","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-07-29","form":"6-K","submitted_at":null,"items":[{"id":21446,"accession_number":"0001214659-26-009162","item_number":"EX-99.1","item_title":"ex99_1.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the results of a General Meeting held on July 29, 2026, where all four shareholder resolutions were passed. Resolutions 1 and 4 authorize a share reorganization reducing outstanding shares by a factor of 10,000 and changing the ADS ratio from 500,000:1 to 50:1, effective July 30, 2026. Resolutions 2 and 3 grant directors authority to allot shares on a non-pre-emptive basis. This is a classic shareholder vote result disclosure under Item 5.07 equivalent, and the share reorganization is material to investors' understanding of capitalization and ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:10:53.007039+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21446,"accession_number":"0001214659-26-009162","item_number":"EX-99.1","item_title":"ex99_1.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the results of a General Meeting held on July 29, 2026, where all four shareholder resolutions were passed. Resolutions 1 and 4 authorize a share reorganization reducing outstanding shares by a factor of 10,000 and changing the ADS ratio from 500,000:1 to 50:1, effective July 30, 2026. Resolutions 2 and 3 grant directors authority to allot shares on a non-pre-emptive basis. This is a classic shareholder vote result disclosure under Item 5.07 equivalent, and the share reorganization is material to investors' understanding of capitalization and ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:10:53.007039+00:00","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-07-29"}]}